These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922 [TBL] [Abstract][Full Text] [Related]
3. Vemurafenib for BRAF V600-Mutant Erdheim-Chester Disease and Langerhans Cell Histiocytosis: Analysis of Data From the Histology-Independent, Phase 2, Open-label VE-BASKET Study. Diamond EL; Subbiah V; Lockhart AC; Blay JY; Puzanov I; Chau I; Raje NS; Wolf J; Erinjeri JP; Torrisi J; Lacouture M; Elez E; Martínez-Valle F; Durham B; Arcila ME; Ulaner G; Abdel-Wahab O; Pitcher B; Makrutzki M; Riehl T; Baselga J; Hyman DM JAMA Oncol; 2018 Mar; 4(3):384-388. PubMed ID: 29188284 [TBL] [Abstract][Full Text] [Related]
4. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm. Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238 [TBL] [Abstract][Full Text] [Related]
5. [Efficacy and safety of vemurafenib in the treatment of BRAF(V600E)-mutated Erdheim-Chester disease]. Liu T; He TH; Niu N; Li J; Zhou DB; Cao XX Zhonghua Xue Ye Xue Za Zhi; 2021 Sep; 42(9):752-756. PubMed ID: 34753230 [No Abstract] [Full Text] [Related]
6. Hypoalphalipoproteinemia and BRAF Cohen-Aubart F; Guerin M; Poupel L; Cluzel P; Saint-Charles F; Charlotte F; Arsafi Y; Emile JF; Frisdal E; Le Goff C; Donadieu J; Amoura Z; Lesnik P; Haroche J; Le Goff W Arterioscler Thromb Vasc Biol; 2018 Aug; 38(8):1913-1925. PubMed ID: 29930009 [TBL] [Abstract][Full Text] [Related]
7. Clinical and positron emission tomography responses to long-term high-dose interferon-α treatment among patients with Erdheim-Chester disease. Cao XX; Niu N; Sun J; Cai H; Wang FD; Wang YN; Duan MH; Zhou DB; Li J Orphanet J Rare Dis; 2019 Jan; 14(1):11. PubMed ID: 30630516 [TBL] [Abstract][Full Text] [Related]
9. Dramatic efficacy of dabrafenib in Erdheim-Chester disease (ECD): a pediatric patient with multiple large intracranial ECD lesions hidden by refractory Langerhans cell histiocytosis. Hao X; Feng R; Bi Y; Liu Y; Li C; Lu T; Tian Y J Neurosurg Pediatr; 2019 Jan; 23(1):48-53. PubMed ID: 30265230 [TBL] [Abstract][Full Text] [Related]
10. BRAF V600E mutation in Juvenile Xanthogranuloma family neoplasms of the central nervous system (CNS-JXG): a revised diagnostic algorithm to include pediatric Erdheim-Chester disease. Picarsic J; Pysher T; Zhou H; Fluchel M; Pettit T; Whitehead M; Surrey LF; Harding B; Goldstein G; Fellig Y; Weintraub M; Mobley BC; Sharples PM; Sulis ML; Diamond EL; Jaffe R; Shekdar K; Santi M Acta Neuropathol Commun; 2019 Nov; 7(1):168. PubMed ID: 31685033 [TBL] [Abstract][Full Text] [Related]
11. [Erdheim-Chester disease (ECD), an inflammatory myeloid neoplasia]. Haroche J; Papo M; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z Presse Med; 2017 Jan; 46(1):96-106. PubMed ID: 27234902 [TBL] [Abstract][Full Text] [Related]
12. Abdominal involvement in Erdheim-Chester disease (ECD): MRI and CT imaging findings and their association with BRAF Nikpanah M; Kim L; Mirmomen SM; Symons R; Papageorgiou I; Gahl WA; O'Brien K; Estrada-Veras JI; Malayeri AA Eur Radiol; 2018 Sep; 28(9):3751-3759. PubMed ID: 29556768 [TBL] [Abstract][Full Text] [Related]
13. An effective treatment in Erdheim Chester disease: vemurafenib: a case report. Bozan E; Darçın T; Yaman S; Yiğenoğlu TN; Kızıl Çakar M; Dal MS; Altuntaş F J Med Case Rep; 2023 Oct; 17(1):426. PubMed ID: 37821987 [TBL] [Abstract][Full Text] [Related]
14. FDA Approval Summary: Vemurafenib for the Treatment of Patients with Erdheim-Chester Disease with the Oneal PA; Kwitkowski V; Luo L; Shen YL; Subramaniam S; Shord S; Goldberg KB; McKee AE; Kaminskas E; Farrell A; Pazdur R Oncologist; 2018 Dec; 23(12):1520-1524. PubMed ID: 30120160 [TBL] [Abstract][Full Text] [Related]
15. High prevalence of BRAF V600E mutations in Erdheim-Chester disease but not in other non-Langerhans cell histiocytoses. Haroche J; Charlotte F; Arnaud L; von Deimling A; Hélias-Rodzewicz Z; Hervier B; Cohen-Aubart F; Launay D; Lesot A; Mokhtari K; Canioni D; Galmiche L; Rose C; Schmalzing M; Croockewit S; Kambouchner M; Copin MC; Fraitag S; Sahm F; Brousse N; Amoura Z; Donadieu J; Emile JF Blood; 2012 Sep; 120(13):2700-3. PubMed ID: 22879539 [TBL] [Abstract][Full Text] [Related]
16. A cytologic diagnosis of BRAF Chasseur P; Kyriakopoulou M; Vokaer B; Beukinga I; Casado Arroyo R; Cogan E; Couturier B Acta Clin Belg; 2017 Oct; 72(5):369-371. PubMed ID: 28222655 [TBL] [Abstract][Full Text] [Related]
17. Young JR; Johnson GB; Murphy RC; Go RS; Broski SM J Nucl Med; 2018 May; 59(5):774-779. PubMed ID: 29097410 [TBL] [Abstract][Full Text] [Related]